Belite Bio

CSO Nathan L. Mata, PhD, will present at the Retinal Therapeutics Innovation Summit, sharing Phase 3 DRAGON topline results for tinlarebant in adolescents with Stargardt disease. Learn more: investors.belitebio.com/news-releases/…

Belite Bio (NASDAQ: BLTE) will participate in four upcoming investor conferences. Additional details are available in the news release. Read more: investors.belitebio.com/news-releases/… #BeliteBio #Investors

We initiated a rolling NDA submission to the U.S. FDA for our investigational oral therapy for Stargardt disease type 1. Learn more: investors.belitebio.com/news-releases/…

▶️WEBCAST: Join us in a fireside chat at the Leerink Global Healthcare Conference on Monday, March 9, 2026 at 1:00 pm ET. Webcast link below. #Webcast #LeerinkPartners #HealthcareConference Webcast Link: event.summitcast.com/view/mT9poctHD…

Belite Bio (NASDAQ: BLTE) to host Webcast on March 2, 2026 to discuss fourth quarter and full year 2025 financial results. #BeliteBio #2025 #FinancialResults #Webcast Webcast: events.q4inc.com/attendee/54761…

🗓️NEWS: Belite Bio will participate in the 41st Asia-Pacific Academy of Ophthalmology (APAO) Congress in Hong Kong this February. The company is set to showcase Phase 3 DRAGON study results for Tinlarebant in Stargardt disease. Read more: investors.belitebio.com/news-releases/…

✅UPDATE: Belite Bio has completed enrollment of 60 patients in its Phase 2/3 DRAGON II clinical trial evaluating Tinlarebant as a potential treatment for Stargardt disease type 1 (STGD1), marking a key clinical milestone for the company. Read more: investors.belitebio.com/news-releases/…

Grateful to our investors for supporting our recently announced $350M offering. This step strengthens our organization as we prepare for commercialization and advance our pipeline. We remain focused on our mission of helping those affected by degenerative retinal diseases.

🔴Today, Belite Bio reported positive topline Phase 3 DRAGON results for Tinlarebant — the first therapeutic candidate to demonstrate efficacy in a global Phase 3 trial in Stargardt disease. Learn more: investors.belitebio.com/news-releases/…

🔴NEWS: Belite Bio (🇺🇸Nasdaq: BLTE) Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease. #Phase3 #BeliteBio #News Read more: investors.belitebio.com/news-releases/…

🔴NEWS: Belite Bio (🇺🇸Nasdaq: BLTE) Announces Up to $275 Million Upsized Private Placement Financing by Leading Healthcare Investors. #BeliteBio #News Read more: investors.belitebio.com/news-releases/…

📅Belite Bio (🇺🇸Nasdaq: BLTE) to Participate in Three Upcoming Investor Conferences. More details in the news release below. #BeliteBio #InvestorConferences Read more: investors.belitebio.com/news-releases/…

🔴Belite Bio (🇺🇸Nasdaq: BLTE) announces registered direct offering of $15 Million. The offering was to a single large existing institutional shareholder. #BeliteBio Read more: investors.belitebio.com/news-releases/…

🔴Belite Bio (🇺🇸Nasdaq: BLTE) to Participate in the H.C. Wainwright Annual Ophthalmology Virtual Conference on Aug 13. Corporate Presentation (7AM EST): journey.ct.events/view/b303b152-… Panel Discussion (11AM EST): journey.ct.events/view/8bb6f7a9-…

🔴Belite Bio (🇺🇸Nasdaq: BLTE) to Host Webcast on August 11, 2025, to Discuss Second Quarter 2025 Financial Results. #BeliteBio #Q2 #FinancialResults #Webcast Webcast: events.q4inc.com/attendee/12746…

📅VIRTUAL EVENT: Belite Bio (🇺🇸Nasdaq: BLTE) to Participate in the BTIG Virtual Biotechnology Conference being held July 29-30, 2025. #BeliteBio #BTIG Read More: investors.belitebio.com/news-releases/…

🔴NEWS: Belite Bio’s (🇺🇸Nasdaq: BLTE) Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy. Read More: investors.belitebio.com/news-releases/…

🔴NEWS: Belite Bio’s (🇺🇸Nasdaq: BLTE) Tinlarebant has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for treatment of STGD1 based on interim data from the ongoing Phase 3 DRAGON trial. Read More: investors.belitebio.com/news-releases/…

📅Belite Bio (🇺🇸Nasdaq: BLTE) will host a webcast on Wednesday, May 14, 2025, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update for the first quarter ended March 31, 2025. #BeliteBio #Q12025 Webcast Link: events.q4inc.com/attendee/13764…

📅Belite Bio announced that the Company will give two poster presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held May 4–8, 2025, in Salt Lake City, Utah. Full Details: investors.belitebio.com/news-releases/…